Lynparza

Active substance

olaparib

Holder

AstraZeneca

Status

closed

Indication

patients with metastatic castration resistant prostate cancer who have progressed on prior NHA and have a BRCA mutation (germline or somatic)

Public documents 

Approbation

Information for the patient

Informed consent

Last update

11/08/2022